Cardiac C-Reactive Protein High Sensitive

High sensitive C-reactive protein (hsCRP) is a strong predictor of cardiovascular disease

High sensitive C-reactive protein (hsCRP) is a strong predictor of cardiovascular disease

Cardiovascular disease (CVD) is a major health burden: a high proportion of patients are not classified correctly or even missed entirely for cardiovascular (CV) risk assessment

More than 60% of those who develop coronary events have only one, or even none of the traditional risk factors, and more than half have either normal or mildly increased lipid values1

European Society of Cardiology’s (ESC) guidelines on CV risk prevention use the SCORE risk charts to estimate a 10-year risk of fatal CV disease, which takes into consideration age, smoking status, systolic blood pressure and total cholesterol2

Additional factors can be added to help further improve overall risk assessment2

Additional biomarkers improve current CV risk assessment

HCY Lp(a) hsCRP

... in combination with conventional analysis ...

HDL   |   LDL


... form a new risk profile and a new test panel that, offers better diagnostics value for CVD.5

The addition of Lipoprotein(a), hsCRP and Homocysteine can add new information to current risk models. This leads to a more accurate categorization of individuals at increased risk for CV disease.
(Montgomery, J.E., Brown, J.R. (2013). Vasc Health Risk Manag. 9, 37-45.)

hsCRP has been shown to be a predictor of CVD in multiple studies

Large scale prospective studies in the US and Europe have consistently shown the predictive value of CRP in CVD3,4

High sensitive C-reactive protein has been shown to be a better predictor of the risk of cardiovascular events than low-density lipoprotein (LDL) cholesterol3,6

In a meta-analysis of 22 studies with an average follow-up of 12 years, the top CRP tertile showed a 58 % increased cardiac risk compared to the bottom CRP tertile7

Benefits

Risk prediction models can be improved by the addition of hsCRP

  • The addition of hsCRP to the Framingham risk score led to a net classification of 11.8% and 5.6% for Coronary Heart Disease (CHD) and Cardiovascular Disease (CVD) respectively1,2
  • More than 20% of all participants with intermediate risk could be reclassified with the addition of hsCRP3

Cardiac C-Reactive Protein High Sensitive

  • Assay time

    10 min

  • Sample material

    Serum, plasma

  • Sample volume

    6 µL

  • Measuring range

    0.15 - 20 mg/L

  • Intermediate precision (cobas c 501 module)

    13.3 mg/L: CV: 2.1 %
    0.53 mg/L: CV: 8.4 %

  • Repeatability (cobas c 501 module)

    15.9 mg/L: CV: 0.4 %
    0.54 mg/L: CV: 1.6 %

Références

 

  1. Young, I., Rifai, N. (2009). High-sensitivity C-reactive protein and cardiovascular disease. Clin Chem. 55, 201-2.
  2. Perk, J. et al. (2012). European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 33(13), 1635-701.
  3. Ridker, P.M. et al. (2002). Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 347, 1557–1565.
  4. Koenig, W. et al. (2004). C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. Mar 23;109(11), 1349-53.
  5. Erqou, S. et al. The Emerging Risk Factors Collaboration. Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality.JAMA. 2009;302(4):412-423. doi:10.1001/jama.2009.1063. 
  6. Yeh, E.T., Willerson, J.T. (2003). Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. Jan 28;107(3), 370-1.
  7. Wald, D.S. et al. (2002). Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325, 1202.